31st Aug 2018 08:18
LONDON (Alliance News) - Pharmaceutical giant AstraZeneca PLC on Friday said the results of its trial of anifrolumab drug showed that it was not effective at treating systemic lupus erythematosus.
The TULIP 1 phase III trial in adults with moderate-to-severe forms of the disease showed that anifrolumab did not cause a statistically significant reduction in disease activity.
A second trial, TULIP 2, is ongoing and the FTSE 100-listed company said it will conduct a full data evaluation when that concludes later this year.
"Systemic lupus erythematosus is a debilitating autoimmune disease with significant unmet need among patients who struggle to achieve meaningful disease control. The result of this trial is disappointing for patients and the lupus community," said AstraZeneca Executive Vice President Sean Bohen.
Shares in AstraZeneca were trading down 0.6% at 5,875.00 pence early Friday.
Related Shares:
Astrazeneca